Ligand Pharmaceuticals
LGND
286.85
-0.09
-0.03%
Ligand Pharmaceuticals
US · LGND
#1920 by market cap
Listed 1970
286.85
-0.09
-0.03%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
B
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Analyst consensus 8 analysts
Buy
Avg price target 367.00 +27.9%
Price target rangecurrent 286.85
Low346.00
Avg367.00
High406.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-12 | H.C. Wainwright | -- | Buy | 358.00 |
| 2026-11-11 | Barclays | -- | Buy | 350.00 |
| 2026-11-05 | Citi | -- | Buy | 402.00 |
| 2026-11-01 | RBC Capital | -- | Buy | 357.00 |
| 2026-10-30 | BofA Securities | -- | Buy | 406.00 |
| 2026-10-30 | Stifel | -- | Buy | 350.00 |
| 2026-10-30 | Barclays | -- | Buy | 345.00 |
| 2026-10-30 | Oppenheimer | -- | Buy | 346.00 |
| 2026-10-29 | Citi | -- | Buy | 397.00 |
| 2026-10-29 | H.C. Wainwright | -- | Buy | 358.00 |
| 2026-10-29 | RBC Capital | -- | Buy | 357.00 |
| 2026-10-19 | BofA Securities | -- | Buy | 406.00 |
| 2026-09-25 | Barclays | -- | Buy | 345.00 |
| 2026-09-24 | Craig-Hallum | -- | Buy | -- |
| 2026-09-24 | H.C. Wainwright | -- | Buy | 358.00 |
| 2026-09-23 | Citi | -- | Buy | 397.00 |
| 2026-09-22 | Craig-Hallum | -- | Buy | -- |
| 2026-09-22 | BofA Securities | -- | Buy | 388.00 |
| 2026-09-22 | Stifel | -- | Buy | -- |
| 2026-09-22 | Citi | -- | Buy | 397.00 |
| 2026-09-21 | H.C. Wainwright | -- | Buy | 358.00 |
| 2026-08-14 | Stifel | -- | Buy | 332.00 |
| 2026-08-12 | Citi | -- | Buy | 390.00 |
| 2026-08-09 | RBC Capital | -- | Buy | 345.00 |
| 2026-08-07 | Craig-Hallum | -- | Buy | 370.00 |
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-29 | -- | ±7.50% | -0.45% (in line) |
| 2026/Q2 | 2026-08-06 | -- | ±7.03% | -0.80% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±6.32% | -9.55% (beat) |
| 2025/Q4 | 2026-02-26 | -- | ±8.12% | +2.50% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±5.73% | +9.37% (beat) |
| 2025/Q2 | 2025-08-07 | -- | ±7.16% | +2.75% (in line) |
| 2025/Q1 | 2025-05-08 | -- | ±11.73% | -2.94% (in line) |
| 2024/Q4 | 2025-02-27 | -- | ±10.17% | +0.57% (in line) |
| 2024/Q3 | 2024-11-07 | -- | ±9.17% | +11.12% (beat) |
| 2024/Q2 | 2024-08-06 | After close | ±9.54% | -5.78% (in line) |
| 2024/Q1 | 2024-05-07 | After close | ±9.58% | +9.75% (beat) |
| 2023/Q4 | 2024-02-27 | -- | ±8.17% | +19.86% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Ligand Pharmaceuticals discussion 0 comments